Skip to main content
. 2021 Oct 19;28(3):468–478. doi: 10.1158/1078-0432.CCR-21-2635

Figure 3.

Figure 3. A, Swimmer plot showing 13 of 28 evaluable patients with evidence of biopsy-proven recurrent disease (above) and N = 15 without recurrent disease (below) after (neo)adjuvant immunotherapy followed by salvage surgery and adjuvant immunotherapy for up to six cycles with anti–PD-1/KIR combination therapy. Each row or bar represents an individual study patient with their time from the start of immunotherapy to date of salvage surgery indicated. The time from surgery to the end of up to six cycles of immunotherapy (28-day cycles) is displayed. Positive margin status at the time of salvage surgery (with tumor on ink) is noted. HPV (human papillomavirus)-positive disease is denoted by a “+.” The date of biopsy-proven recurrence (if applicable) is plotted along with last known follow-up (censored) or date of death. B, Clinicopathologic features of individuals experiencing recurrence (N = 13) sorted by pathologic downstaging from pre-op (clinical stage) to post-op (pathologic stage), margin status (positive defined as tumor on ink), lymph node status (ENE = extranodal extension) if sampled, and number (#) of adjuvant cycles of immunotherapy received post-op (six total cycles were planned; 28-day cycle length).

A, Swimmer plot showing 13 of 28 evaluable patients with evidence of biopsy-proven recurrent disease (above) and N = 15 without recurrent disease (below) after (neo)adjuvant immunotherapy followed by salvage surgery and adjuvant immunotherapy for up to six cycles with anti–PD-1/KIR combination therapy. Each row or bar represents an individual study patient with their time from the start of immunotherapy to date of salvage surgery indicated. The time from surgery to the end of up to six cycles of immunotherapy (28-day cycles) is displayed. Positive margin status at the time of salvage surgery (with tumor on ink) is noted. HPV (human papillomavirus)-positive disease is denoted by a “+.” The date of biopsy-proven recurrence (if applicable) is plotted along with last known follow-up (censored) or date of death. B, Clinicopathologic features of individuals experiencing recurrence (N = 13) sorted by pathologic downstaging from pre-op (clinical stage) to post-op (pathologic stage), margin status (positive defined as tumor on ink), lymph node status (ENE = extranodal extension) if sampled, and number (#) of adjuvant cycles of immunotherapy received post-op (six total cycles were planned; 28-day cycle length).